Suppression of Ehrlich subcutaneous solid tumor growth by immunization with ganglioside GT1b of its origin, its IgM antibody or anti-idiotype antibody.
Mice vaccinated with purified Ehrlich tumor-plasma GT1b admixed with Freund's adjuvant suppressed subcutaneous growth of the same tumor cells inoculated in vivo by 37.9%. The suppression was dose-dependent and was a result of humoral immune response against GT1b. Further, when mice were injected with varying doses of rabbit polyclonal anti-GT1b IgM antibody and challenged with Ehrlich tumor cells subcutaneously, a significant reduction in tumor growth (47.3%) was observed. Again, the suppression was dose-dependent. To strengthen furthier the observed therapeutic potential of this immunogenic GT1b, mice were immunized with anti-idiotype antibodies to GT1b raised in female Sprague Dawley rats by immunization with rabbit anti-GT1b IgM, which is expected to carry the structural image of GT1b. Immunization of mice with this anti-idiotype antibody was observed to suppress Ehrlich subcutaneous solid tumor growth by 60%. The results indicated therapeutic potential of immunogenic tumor-associated ganglioside in solid tumor model.
Saha
S
S
Dept. of Metabolic Regulation, Chittaranjan National Cancer Institute, Calcutta, India.
Mondal
S
S
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000917:Antibody Formation; D002286:Carcinoma, Ehrlich Tumor / Q000097:blood / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D005732:Gangliosides / Q000097:blood / Q000276:immunology*; D007074:Immunoglobulin G / Q000627:therapeutic use; D007075:Immunoglobulin M / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods; D008297:Male; D051379:Mice; D011817:Rabbits
D000888:Antibodies, Anti-Idiotypic; D005732:Gangliosides; D007074:Immunoglobulin G; D007075:Immunoglobulin M; C016481:trisialoganglioside GT1